共 56 条
[1]
[2]
[3]
[4]
[5]
[6]
[7]
Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized; open‐label; prospective study ( VISION )[J] L.‐N. Ji;C.‐Y. Pan;J.‐M. Lu;H. Li;D.‐L. Zhu;Q. Li;Q.‐F. Li;Y.‐D. Peng;H.‐M. Tian;C. Yao;Z.‐G. Zhao;L. Wang;B.‐H. Wang Diabetes; Obesity and Metabolism 2016,
[8]
Effects of body mass index or dosage on gastrointestinal disorders associated with extended-release metformin in type 2 diabetes: Sub-analysis of a Phase IV open-label trial in Chinese patients[J] Lixin Guo;Xiaohui Guo;Yan Li;Xu Hong;Xiaozhen Jiang;Qing Su;Dong Zhao;Xiaojing Wu;Linong Ji Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2016,
[9]
Association between metformin therapy and incidence; recurrence and mortality of prostate cancer: evidence from a meta‐analysis[J] Dan Deng;Yuan Yang;Xiaojun Tang;Laura Skrip;Jingfu Qiu;Yang Wang;Fan Zhang Diabetes Metab Res Rev 2015,
[10]
Metformin and lung cancer risk of patients with type 2 diabetes mellitus:A meta?analysis[J] Ning Zhu;Yuanyuan Zhang;Yi Gong;Jian He;Xiaodong Chen Biomedical Reports 2015,

